Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesClofarabine in the treatment of poor risk acute myeloid leukaemia
Hematological Oncology, 09/22/09
Krawczyk J et al. – Clofarabine is a second generation nucleoside analogue. It inhibits DNA repair and activates the mitochondrial apoptotic pathway leading to cell death. Clofarabine (alone or in combination) is active in poor risk AML with an acceptable safety profile and should be considered a potential option in poor risk AML patients.
Related Articles
Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome
Cancer, 10/29/09
Relevance Score: 94%
Daunorubicin Versus Mitoxantrone Versus Idarubicin as Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10
Journal of Clinical Oncology, 10/23/09
Relevance Score: 94%
Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives
Current Opinion in Oncology, 10/14/09
Relevance Score: 94%
FLT3 inhibition as a targeted therapy for acute myeloid leukemia
Current Opinion in Oncology, 10/14/09
Relevance Score: 94%
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome
Blood, 10/02/09
Relevance Score: 94%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Drug Approval Summary: Bevacizumab (Avastin) as Treatment of Recurrent Glioblastoma Multiforme
The Oncologist, 12/02/09
Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: A randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers
Clinical Therapeutics, 12/01/09
Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors
Clinical Cancer Research, 12/01/09
Sponsor
Article Search
Sponsor